

# Andrew Zloza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1842191/publications.pdf>

Version: 2024-02-01

89  
papers

3,778  
citations

201658

27  
h-index

144002

57  
g-index

102  
all docs

102  
docs citations

102  
times ranked

6135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncolytic viruses: a new class of immunotherapy drugs. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 642-662.	46.4	1,055
2	Malignancies in HIV/AIDS. <i>Aids</i> , 2014, 28, 453-465.	2.2	197
3	Pro-Inflammatory Chemokine CCL2 (MCP-1) Promotes Healing in Diabetic Wounds by Restoring the Macrophage Response. <i>PLoS ONE</i> , 2014, 9, e91574.	2.5	192
4	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1119-1128.	7.1	140
5	Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. <i>Nature Medicine</i> , 2017, 23, 100-106.	30.7	121
6	First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4163-4169.	7.0	119
7	Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. <i>Frontiers in Oncology</i> , 2017, 7, 202.	2.8	107
8	Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo. <i>Science Translational Medicine</i> , 2013, 5, 174ra28.	12.4	100
9	CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2017, 127, 1271-1283.	8.2	100
10	MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	97
11	Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. , 2016, 4, 12.		79
12	Active $\beta$ -Catenin Signaling Is an Inhibitory Pathway for Human Immunodeficiency Virus Replication in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2008, 82, 2813-2820.	3.4	78
13	Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. <i>Onc Immunology</i> , 2019, 8, e1591875.	4.6	78
14	Antigenic peptide nanofibers elicit adjuvant-free CD8+ T cell responses. <i>Vaccine</i> , 2014, 32, 1174-1180.	3.8	73
15	HSP70i is a critical component of the immune response leading to vitiligo. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 88-98.	3.3	70
16	CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. <i>Blood</i> , 2003, 102, 2156-2164.	1.4	63
17	NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responses. <i>Nature Medicine</i> , 2012, 18, 422-428.	30.7	56
18	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. <i>Journal of Clinical Investigation</i> , 2018, 128, 2325-2338.	8.2	52

#	ARTICLE	IF	CITATIONS
19	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. , 2015, 3, 18.		51
20	Enhancing the Magnitude of Antibody Responses through Biomaterial Stereochemistry. ACS Biomaterials Science and Engineering, 2015, 1, 601-609.	5.2	48
21	Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. , 2019, 7, 136.		48
22	A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. Pigment Cell and Melanoma Research, 2018, 31, 534-540.	3.3	42
23	Multiple populations of T lymphocytes are distinguished by the level of CD4 and CD8 coexpression and require individual consideration. Journal of Leukocyte Biology, 2006, 79, 4-6.	3.3	39
24	Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface. Blood, 2009, 114, 3841-3853.	1.4	38
25	Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy. Vaccines, 2021, 9, 1497.	4.4	38
26	Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. , 2014, 2, 1.		35
27	Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine, 2017, 12, 2693-2706.	3.3	32
28	IFN-lambda therapy: current status and future perspectives. Drug Discovery Today, 2016, 21, 167-171.	6.4	31
29	IFN- $\gamma$ cancer immunotherapy: new kid on the block. Immunotherapy, 2016, 8, 877-888.	2.0	30
30	Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CV21) in melanoma patients: Interim results of the CAPRA clinical trial. Cancer Research, 2017, 77, CT026-CT026.	0.9	30
31	Interferon Lambda: Toward a Dual Role in Cancer. Journal of Interferon and Cytokine Research, 2019, 39, 22-29.	1.2	29
32	Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs of Today, 2015, 51, 549.	1.1	29
33	$\beta$ -Catenin Signaling Mediates CD4 Expression on Mature CD8+ T Cells. Journal of Immunology, 2010, 185, 2013-2019.	0.8	25
34	IFN- $\gamma$ : A New Inducer of Local Immunity against Cancer and Infections. Frontiers in Immunology, 2016, 7, 598.	4.8	25
35	Concerted action of IFN- $\gamma$ and IFN- $\alpha$ induces local NK cell immunity and halts cancer growth. Oncotarget, 2016, 7, 49259-49267.	1.8	23
36	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Reports, 2016, 17, 957-965.	6.4	22

#	ARTICLE	IF	CITATIONS
37	Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 748.	2.8	20
38	Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound. <i>ELife</i> , 2022, 11, .	6.0	19
39	Development of Tumor-Infiltrating CD8+ T Cell Memory Precursor Effector Cells and Antimelanoma Memory Responses Are the Result of Vaccination and TGF- $\beta$ 2 Blockade during the Perioperative Period of Tumor Resection. <i>Journal of Immunology</i> , 2011, 186, 3309-3316.	0.8	18
40	Supramolecular Peptide Nanofibers Engage Mechanisms of Autophagy in Antigen-Presenting Cells. <i>ACS Omega</i> , 2017, 2, 9136-9143.	3.5	17
41	Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+T cells and autoimmune vitiligo. <i>Autoimmunity</i> , 2011, 44, 599-606.	2.6	15
42	HIV Infection Accelerates Gastrointestinal Tumor Outgrowth in NSG-HuPBL Mice. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 677-684.	1.1	14
43	Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. <i>Journal of Translational Medicine</i> , 2014, 12, 113.	4.4	14
44	Results of a Randomized Phase I Gene Therapy Clinical Trial of Nononcolytic Fowlpox Viruses Encoding T Cell Costimulatory Molecules. <i>Human Gene Therapy</i> , 2014, 25, 452-460.	2.7	14
45	Viruses, bacteria, and parasites “oh my! a resurgence of interest in microbial-based therapy for cancer. , 2018, 6, 3.		14
46	CD8 Co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor- $\beta$ 2 (TGF- $\beta$ 2)-mediated suppression. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 291-297.	4.2	13
47	Infection: a Cause of and Cure for Cancer. <i>Current Pharmacology Reports</i> , 2017, 3, 315-320.	3.0	13
48	Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. <i>Oncogene</i> , 2018, 37, 3672-3685.	5.9	13
49	Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following <sc>ONC</sc>201 treatment. <i>British Journal of Haematology</i> , 2019, 185, 133-136.	2.5	11
50	Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions. <i>Frontiers in Immunology</i> , 2019, 10, 4.	4.8	11
51	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 1483.	2.8	10
52	Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 9-16.	4.2	9
53	Priming with very low-affinity peptide ligands gives rise to CD8+ T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF) $\beta$ 2-mediated suppression. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1543-1551.	4.2	8
54	CD8+ T Cells Sabotage Their Own Memory Potential through IFN- $\gamma$ -Dependent Modification of the IL-12/IL-15 Receptor $\beta$ Axis on Dendritic Cells. <i>Journal of Immunology</i> , 2012, 188, 3639-3647.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. Cancer Research, 2021, 81, CT139-CT139.	0.9	8
56	Editorial: Tumor Microenvironment and Resistance to Current Therapies. Frontiers in Oncology, 2019, 9, 1131.	2.8	7
57	A phase 1b dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. European Journal of Medical Research, 2022, 27, .	2.2	7
58	High-Dose IL-2 Induces Rapid Albumin Uptake by Endothelial Cells Through Src-Dependent Caveolae-Mediated Endocytosis. Journal of Interferon and Cytokine Research, 2014, 34, 915-919.	1.2	6
59	Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression. Cancers, 2022, 14, 2923.	3.7	6
60	Immune Modulation of HIV Replication: Relevance to HIV Immuno- and Neuro-Pathogenesis. Current HIV Research, 2004, 2, 395-401.	0.5	4
61	A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).. Journal of Clinical Oncology, 2018, 36, TPS219-TPS219.	1.6	4
62	HIV Infection Leads to Redistribution of Leaky Claudin-2 in the Intestine of Humanized SCID IL-2R <sup>α</sup> Hu-PBMC Mice. AIDS Research and Human Retroviruses, 2015, 31, 774-775.	1.1	3
63	CD4+ T Cells. , 2014, , 1-13.		3
64	Phase 1b study of intratumoral oncolytic coxsackievirus A21 (CVA21) and pembrolizumab in subjects with advanced melanoma. Annals of Oncology, 2016, 27, vi400.	1.2	2
65	Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.. Journal of Clinical Oncology, 2018, 36, 2595-2595.	1.6	2
66	Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment. , 2014, 2, .		1
67	Single-step nanoparticle antigen presentation system for tumor immunotherapy. , 2015, 3, P319.		1
68	CD4+ T Cells. , 2017, , 117-129.		1
69	DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS. Neuro-Oncology, 2018, 20, vi72-vi72.	1.2	1
70	Double-Humanized Mouse Model to Study Bone Morphogenetic Protein (BMP) Signaling in Tumor Xenografts. Methods in Molecular Biology, 2019, 1891, 257-262.	0.9	1
71	Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients.. Journal of Clinical Oncology, 2017, 35, 2586-2586.	1.6	1
72	Abstract 124: Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
73	Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival. , 2013, 1, .		0
74	PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses. , 2013, 1, .		0
75	The impact of age on a mitoxantrone-based tumor vaccine. , 2013, 1, P234.		0
76	Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilockâ€™s Complex. , 2013, 1, .		0
77	Tu1692 HIV Infection Accelerates Gastrointestinal Tumor Outgrowth in Humanized NSG-HuPBL Mice. Gastroenterology, 2014, 146, S-820.	1.3	0
78	Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy. , 2015, 3, P281.		0
79	Combination Radiation Therapy and Imipridone ONC201 for the Treatment of Solid Tumors. International Journal of Radiation Oncology Biology Physics, 2017, 99, E598-E599.	0.8	0
80	ACTR-51. CLINICAL EVALUATION OF THE IMIPRIDONE ONC201 IN RECURRENT GLIOBLASTOMA: PREDICTIVE AND PHARMACODYNAMIC BIOMARKER ANALYSES. Neuro-Oncology, 2017, 19, vi11-vi12.	1.2	0
81	A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology, 2015, 33, TPS3095-TPS3095.	1.6	0
82	Magnesium alterations of graft immune cells (MAGIC).. Journal of Clinical Oncology, 2017, 35, e18541-e18541.	1.6	0
83	Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses. , 2018, , .		0
84	A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies.. Journal of Clinical Oncology, 2018, 36, TPS80-TPS80.	1.6	0
85	Abstract 5568: Clinical immunostimulatory activity of imipridone ONC201, a selective DRD2 antagonist, in advanced solid tumor patients. , 2018, , .		0
86	Abstract 2765: Combination ONC201 and radiation therapy in the treatment of breast cancer. , 2018, , .		0
87	Abstract LB-189: Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. , 2018, , .		0
88	Gut Microbial Shifts Indicate Melanoma Presence and Bacterial Interactions in a Murine Model. Diagnostics, 2022, 12, 958.	2.6	0
89	Abstract 249: Combination of ONC201 with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers. , 2019, , .		0